Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 27, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease
September 20, 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 or 60 mg; mean mHTT reduction across both cohorts...
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
September 16, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced program currently in development using...
Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022
July 28, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
June 14, 2022 09:00 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
May 25, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Delivered first clinical data demonstrating target engagement and translation of PN chemistry’s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9 clinical trial to optimize dose level and...
Wave Life Sciences to Present at Upcoming Investor Conferences
May 10, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022
May 05, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...